Isopropylamine NONOate (IPA/NO) moderates neointimal hyperplasia following vascular injury

Journal of Vascular Surgery

Volumn 51, Issue 5, 2010, Pages 1248-1259

  Tsihlis, Nick D ^a   Murar, Jozef ^a   Kapadia, Muneera R ^a   Ahanchi, Sadaf S ^b   Oustwani, Christopher S ^a   Saavedra, Joseph E ^c   Keefer, Larry K ^d   Kibbe, Melina R ^a,e  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c SAIC FREDERICK INC   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN A; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; EVANS BLUE; INOTROPIC AGENT; ISOPROPYLAMINE NONOATE; PROTEIN P21; UNCLASSIFIED DRUG; 1 ISOPROPYLDIAZEN 1 IUM 1,2 DIOLATE; 1-ISOPROPYLDIAZEN-1-IUM-1,2-DIOLATE; HYDRAZINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL INJURY; CAROTID ARTERY INJURY; CELL CYCLE; CELL DEATH; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MORPHOMETRICS; NEOINTIMA; NEOINTIMA HYPERPLASIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; S PHASE CELL CYCLE CHECKPOINT; SMOOTH MUSCLE FIBER; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING; ABDOMINAL AORTA; ANIMAL; CELL CULTURE; COMPARATIVE STUDY; CYTOLOGY; DISEASE MODEL; DRUG EFFECT; ENDOTHELIUM CELL; HYPERPLASIA; INTIMA; MALE; METABOLISM; PATHOLOGY; RANDOMIZATION; REFERENCE VALUE; SPRAGUE DAWLEY RAT; UMBILICAL VEIN;

ANIMALS; AORTA, ABDOMINAL; BLOTTING, WESTERN; CAROTID ARTERY INJURIES; CELL DEATH; CELL PROLIFERATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; HUMANS; HYDRAZINES; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; MALE; MUSCLE, SMOOTH, VASCULAR; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; REFERENCE VALUES; TUNICA INTIMA; UMBILICAL VEINS;

EID: 77952312344     PISSN: 07415214     EISSN: 10976809     Source Type: Journal    
DOI: 10.1016/j.jvs.2009.12.028     Document Type: Article

References (37)

1. Drago RS, Karstetter BR. The reaction of nitrogen(II) oxide with various primary and secondary amines. J Am Chem Soc 1961;83: 1819-22.
2. Fukuto JM, Bartberger MD, Dutton AS, Paolocci N, Wink DA, Houk KN. The physiological chemistry and biological activity of nitroxyl (HNO): the neglected, misunderstood, and enigmatic nitrogen oxide. Chem Res Toxicol 2005;18:790-801.
3. Dutton AS, Suhrada CP, Miranda KM, Wink DA, Fukuto JM, Houk KN. Mechanism of pH-dependent decomposition of monoalkylamine diazeniumdiolates to form HNO and NO, deduced from the model compound methylamine diazeniumdiolate, density functional theory, and CBS-QB3 calculations. Inorg Chem 2006;45:2448-56.
4. Bonner FT, Ravid B. Thermal decomposition of oxyhyponitrite (sodium trioxodinitrate(II)) in aqueous solution. Inorg Chem 1975;14:558-63.
5. Hughes MN, Wimbledon PE. The chemistry of trioxodinitrates. 1. Decomposition of sodium trioxdinitrate (Angeli's salt) in aqueous solution. J Chem Soc Dalton Trans 1976;8:703-7.
6. Paolocci N, Katori T, Champion HC, St JM, Miranda KM, Fukuto JM, et al. Positive inotropic and lusitropic effects ofHNO/NO-in failing hearts: independence from beta-adrenergic signaling. Proc Natl Acad Sci USA 2003;100:5537-42.
7. Fukuto JM, Chiang K, Hszieh R, Wong P, Chaudhuri G. The pharmacological activity ofnitroxyl: a potent vasodilator with activity similar to nitric oxide and/or endothelium-derived relaxing factor. J Pharmacol Exp Ther 1992;263:546-51.
8. - donation byS-nitrosothiols: implications for regulation ofphysiological functions by S-nitrosylation and acceleration of disulfide formation. Arch Biochem Biophys 1995; 318:279-85.
9. Wong PS, Hyun J, Fukuto JM, Shirota FN, De Master EG, Shoeman DW, et al. Reaction between S-nitrosothiols and thiols: generation ofnitroxyl (HNO) and subsequent chemistry. Biochemistry 1998;37:5362-71.
10. Irvine JC, Favaloro JL, Widdop RE, Kemp-Harper BK. Nitroxyl anion donor, Angeli's salt, does not develop tolerance in rat isolated aortae. Hypertension 2007;49:885-92.
11. 2+ cycling. Circ Res 2007;100:96-104.
12. Feelisch M. Nitroxyl gets to the heart of the matter. Proc Natl Acad Sci USA 2003;100:4978-80.
13. Yu SM, Hung LM, Lin CC. cGMP-elevating agents suppress proliferation of vascular smooth muscle cells by inhibiting the activation of epidermal growth factor signaling pathway. Circulation 1997;95: 1269-77.
14. Kibbe MR, Li J, Nie S, Watkins SC, Lizonova A, Kovesdi I, et al. Inducible nitric oxide synthase (iNOS) expression upregulates p21 and inhibits vascular smooth muscle cell proliferation through p42/44 mitogen-activated protein kinase activation and independent of p53 and cyclic guanosine monophosphate. J Vasc Surg 2000;31:1214-28.
15. Maragos CM, Morley D, Wink DA, Dunams TM, Saavedra JE, Hoffman A, et al. Complexes of.NO with nucleophiles as agents for the controlled biological release of nitric oxide. Vasorelaxant effects. J Med Chem 1991;34:3242-7.
16. Ahanchi SS, Varu VN, Tsihlis ND, Martinez J, Pearce CG, Kapadia MR, et al. Heightened efficacy of nitric oxide-based therapies in type II diabetes mellitus and metabolic syndrome. Am J Physiol Heart Circ Physiol 2008;295:H2388-98.
17. Kapadia MR, Chow LW, Tsihlis ND, Ahanchi SS, Eng JW, Murar J, et al. Nitric oxide and nanotechnology: a novel approach to inhibit neo-intimal hyperplasia. J Vasc Surg 2008;47:173-82.
18. Han J, Talorete TP, Yamada P, Isoda H. Anti-proliferative and apopto-tic effects of oleuropein and hydroxytyrosol on human breast cancer MCF-7 cells. Cytotechnology 2009;59:45-53.
19. Kibbe MR, Nie S, Seol DW, Kovesdi I, Lizonova A, Makaroun M, etal. Nitric oxide prevents p21 degradation with the ubiquitin-proteasome pathway in vascular smooth muscle cells. J Vasc Surg 2000;31:364-74.
20. Pearce CG, Najjar SF, Kapadia MR, Murar J, Eng J, Lyle B, et al. Beneficial effect of a short-acting NO donor for the prevention of neointimal hyperplasia. Free Radic Biol Med 2008;44:73-81.
21. Shears LL, Kibbe MR, Murdock AD, Billiar TR, Lizonova A, Kovesdi I, et al. Efficient inhibition of intimal hyperplasia by adenovirus-mediated inducible nitric oxide synthase gene transfer to rats and pigs in vivo. J Am Coll Surg 1998;187:295-306.
22. Shafirovich V, Lymar SV. Nitroxyl and its anion in aqueous solutions: spin states, protic equilibria, and reactivities toward oxygen and nitric oxide. Proc Natl Acad Sci USA 2002;99:7340-5.
23. Miranda KM, Katori T,Torres de Holding CL, Thomas L,Ridnour LA, McLendon WJ, et al. Comparison of the NO and HNO donating properties ofdiazeniumdiolates: primary amine adducts release HNO in vivo. J Med Chem 2005;48:8220-8.
24. Paolocci N, Saavedra WF, Miranda KM, Martignani C, Isoda T, Hare JM, et al. Nitroxyl anion exerts redox-sensitive positive cardiac inotropy in vivo by calcitonin gene-related peptide signaling. Proc Natl Acad Sci USA 2001;98:10463-8.
25. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989;83:1774-7.
26. Guo JP, Panday MM, Consigny PM, Lefer AM. Mechanisms ofvascular preservation by a novel NO donor following rat carotid artery intimal injury. Am J Physiol 1995;269:H1122-31.
27. Nishio E, Fukushima K, Shiozaki M, Watanabe Y. Nitric oxide donor SNAP induces apoptosis in smooth muscle cells through cGMP-independent mechanism. Biochem Biophys Res Commun 1996;221: 163-8.
28. Iwashina M, Shichiri M, Marumo F, Hirata Y. Transfection of inducible nitric oxide synthase gene causes apoptosis in vascular smooth muscle cells. Circulation 1998;98:1212-8.
29. Sarkar R, Gordon D, Stanley JC, Webb RC. Cell cycle effects of nitric oxide on vascular smooth muscle cells. Am J Physiol 1997;272:H1810-8.
30. Sato J, Nair K, Hiddinga J, Eberhardt NL, Fitzpatrick LA, Katusic ZS, et al. eNOS gene transfer to vascular smooth muscle cells inhibits cell proliferation via upregulation of p27 and p21 and not apoptosis. Cardiovasc Res 2000;47:697-706.
31. Bayes-Genis A, Campbell JH, Carlson PJ, Holmes DR, Jr., Schwartz RS. Macrophages, myofibroblasts and neointimal hyperplasia after coronary artery injury and repair. Atherosclerosis 2002;163:89-98.
32. Pollman MJ, Hall JL, Gibbons GH. Determinants of vascular smooth muscle cell apoptosis after balloon angioplasty injury. Influence of redox state and cell phenotype. Circ Res 1999;84:113-21.
33. Shi Y, O'Brien JE, Fard A, Mannion JD, Wang D, Zalewski A. Adven-titial myofibroblasts contribute to neointimal formation in injured porcine coronary arteries. Circulation 1996;94:1655-64.
34. Wink DA, Feelisch M, Fukuto J, Chistodoulou D, Jourd'heuil D, Grisham MB, et al. The cytotoxicity of nitroxyl: possible implications for the pathophys-iological role of NO. Arch Biochem Biophys 1998;351:66-74.
35. Ragsdale RO, Karstetter BR, Drago RS. Decomposition of the adducts of diethylamine and isopropylamine with nitrogen(II) oxide. Inorg Chem 1965;4:420-2.
36. Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007;356:989-97.
37. Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, Wallen-tin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007;356:1009-19.